Pivotal trial results for inclisiran in the treatment of heterozygous familial hypercholesterolemia (HeFH) were published on January 1, 2022. The publication details the findings from the ORION-9 trial, which evaluated the effect of inclisiran on low-density lipoprotein cholesterol (LDL-C) levels.
Background
Inclisiran is a medication studied for the treatment of heterozygous familial hypercholesterolemia (HeFH). This condition is characterized by high levels of LDL-C, increasing the risk of cardiovascular disease.
Trial design
The published trial, known as ORION-9, was designed to evaluate the effect of inclisiran treatment on low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH). The study aimed to assess the drug's impact on this key lipid parameter.
What this means
The publication of these pivotal trial results for inclisiran means that the data regarding its effect on LDL-C in patients with heterozygous familial hypercholesterolemia (HeFH) is now available for review by clinicians, researchers, and patient advocates. While specific quantitative outcomes are not detailed in this summary, the availability of the full publication allows for a comprehensive understanding of the trial's findings and their potential implications for patient care.
Source
The information for this update is based on a pivotal publication titled 'Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia,' which appeared in the New England Journal of Medicine. This publication was indexed on PubMed on January 1, 2022, and is accessible via pubmed.ncbi.nlm.nih.gov.